Boehringer Ingelheim agreed to invest $10 billion in U.S. R&D and manufacturing through 2028 and to join the TrumpRx.gov direct purchasing platform under a deal with the Trump administration. As part of the arrangement the company secured an exemption from Section 232 tariffs and committed capital expenditures aimed at expanding domestic manufacturing and supply resilience. Boehringer described the deal as a way to lower medicine costs for Americans while bolstering U.S. production capacity for chronic disease medicines. The agreement underscores growing industry participation in administration-led pricing initiatives in exchange for trade and regulatory concessions.